US pharma giant Merck backs healthcare marketplace HD in Southeast Asia
Big Tech and pharmaceutical companies are accelerating the implementation of artificial intelligence in the healthcare ...
BioSpace19h
SpringWorks Wins FDA Nod for Neurofibromatosis Drug, Tees Up Challenge to AstraZeneca
The FDA on Tuesday signed off on SpringWorks Therapeutics’ mirdametinib—now to carry the brand name Gomekli—for the treatment ...
Pharmaceutical Technology on MSN21h
FDA approves Gomekli as first neurofibromatosis drug for adults
The US Food and Drug Administration (FDA) has approved SpringWorks Therapeutics’ Gomekli (mirdametinib) to treat ...
BioSpace22h
New M&A Action, BMS’ Ongoing Cost Cuts and the Insatiable Demand for Weight Loss Drugs
Novartis, Eli Lilly and more put on their deal-making caps, Bristol Myers Squibb targets $2 billion in savings through 2027, ...
US FDA approves SpringWorks' genetic disorder drug
The U.S. Food and Drug Administration said on Tuesday it has approved SpringWorks Therapeutics' drug to treat a type of rare ...
Nature1d
Dozens of new obesity drugs are coming: these are the ones to watch
Next-generation obesity drugs will work differently from Ozempic and Wegovy — aiming to deliver greater weight loss with ...
Germany's Merck in advanced talks to acquire US biotech firm SpringWorks
(Corrects third to last paragraph to say "the erosion from LOEs (loss of exclusivity)", not "from LOEs (levels of evidence)") ...
BioPharma Dive1d
Merck KGaA pursuing Springworks; BridgeBio wins EU drug OK
The German drugmaker confirmed acquisition talks, but cautioned a deal may not materialize. Elsewhere, Biohaven got priority ...
24/7 Wall St.5d
Wall Street Analysts Thought Merck Stock Had 10% Downside Risk Heading Into Earnings. That Materialized, So What's Next?
Merck & Co. (NYSE:MRK) is a prominent American multinational pharmaceutical company many investors know for its brand-name ...